VEGFA and viral infectious disease: However, as noted, there are several additional models of COPD, including those involving enhanced MMP or IL-13 expression, repetitive viral infections, chemical models with vascular endothelial growth factor (VEGF) inhibitors, and NO2 exposure models (96–99).